Our Expertise
Our Team
Contact Us
Sanjay Sehgal
Duncan Moore
Hans Brenner
Ram Radhakrishnan
Shicai Lin

Our Team

Sanjay Sehgal - Managing Partner & CEO
Sanjay was a Partner at Schroder Capital Partners (Asia), based in Singapore. He brings 13 years of Asian private equity experience, having led or co-led investments worth over $310 million of equity.

Sanjay helped pioneer the entry of the Schroder Funds' into the Healthcare and Life Sciences domain and geographically into India. Sanjay was an active Board member of private and listed companies in which the Schroder Funds' invested. He was a member of the Investment Committee, for the Schroder Funds' which had $625 million under management and was keenly involved in the negotiated deals in India, USA, Latin America, China, Australasia and Singapore.

He is currently a Board Member and Chairman of the Audit Committee of an Australian-listed company, ITL Limited.

Prior to joining Schroder Capital Partners, Sanjay worked at LEK Consulting in London and Boston. Previously, he was a Member of Technical Staff at GTE Laboratories (now Verizon) in USA.

Sanjay has a MBA in Finance with distinction, from The Wharton School, Philadelphia, PA; an MSc in Telecommunications from Columbia University, NY; and a Bachelors degree in Technology (Elec. Engg.), from IIT (Bombay).

Sanjay was elected as Hon. Secretary, Singapore Venture Capital & Private Equity Association for 2005 and as Hon. Treasurer in 2004.

He has spoken at numerous healthcare and private equity conferences around the globe.
Back to top

Duncan Moore - Partner

Duncan Moore formally joined East West Capital Partners in May 2008 having served informally as an advisor since early 2007.

Duncan was a top ranked pharmaceutical analyst at Morgan Stanley from 1991 to 2008 and was a Managing Director from 1997 to 2008 leading the firmís global healthcare equity research team. He was the lead analyst on the European pharmaceutical industry stocks and led the equity research part of the initial public offerings of numerous companies including Wellcome PLC, Sulzer Medica, Biora, deCODE Genetics, Almirall, Grifols and, Grupo Rovi.

As part of his responsibilities at Morgan Stanley Duncan ran an ideas model portfolio in global healthcare. This involved visiting Asia and India in particular, every year for the last 5 years. It was during these visits that he became aware of the enormity of the expansion capital investment opportunity in the region.

Whilst at the University of Cambridge he co-founded a medical diagnostics company called Ultra Clone with two colleagues which led to the beginnings of a 20 year career in healthcare capital markets analysis. In 1986 he was involved in setting up the Bank Invest biotechnology funds and was on the scientific advisory board.

Duncan was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology. He has an M.Phil and Ph.D. from the University of Cambridge where he was also a post doctoral research fellow.
Back to top

Hans Brenner - Venture Partner
Hans Brenner has over 14 years of experience with B. Braun Melsungen, AG, a privately held German company and one of the largest medical devices companies in Europe.

Hans was keenly involved in several acquisitions and joint venture transactions worth over US$310 million in Europe and Asia. He was a key executive responsible for valuation, negotiations and post-merger integration in most of these transactions.

As President of B. Braun's Asia Pacific operations for 7 years based in Penang, Malaysia, Hans was responsible for a Ä400 million business with 6500 employees. His team building and leadership skills enabled the company to clock a double-digit growth rate annually.

Further, Hans was instrumental in restructuring the operations from a loss-making subsidiary to one of the most-profitable in the B. Braun group.

Hans has initiated major development and production projects in India and China and is an expert in medical devices and technology in these countries and across the region.

With a Masters degree in Economical Science, from the University of Stuttgart, Hans started his career with Price Waterhouse Coopers and did considerable amount of research, consultancy, and M&A work, prior to joining Aesculap and merging that company with B.Braun.
Back to top

Ram Radhakrishnan - Venture Partner

Ram has over 30 years experience in operations, manufacturing, strategy and business development with pharmaceutical companies worldwide.

His last assignment of 12 years was with Strides Arcolab Limited, a US$280 million market cap Indian generic pharmaceutical, contract manufacturing and research company based in Bangalore. As Executive Director he focused on manufacturing, growth and strategy of the company. Strides grew 300-fold during his 12 year tenure.

Most recently, over the last 5 years, Ram was CEO of Strides Inc, the US subsidiary of Strides Arcolab. He was fully involved in the negotiations and acquisition of this subsidiary. Ram provided the leadership and created the team that enabled turning this into a viable entity. He ensured securing US FDA approval for the plant and raised additional funding for expansion and growth.

Ram started his career in the pharmaceutical division of ICI in India and spent five years there with progressively growing responsibilities. He was an entrepreneur at age 26 and built a pharmaceutical plant in Goa, India on a green field site and sold it after 7 years. Thereafter, Ram was keenly involved with a few other pharmaceutical companies in Germany, India and Hong Kong.

Ram has a Bachelors in Physics and a Masters in Economics.
Back to top

Shicai Lin - Advisor

Shicai Lin is an advisor to East West Capital Partners and is responsible for evaluating and conducting due diligence on potential investments in China and on potential technology transfers to China. Shicai is a University educated biologist and pharmacologist with some industrial experience gained from a one-year industrial placement working within the strategy & investment team at Harbin Pharmaceutical Group which is one of the largest pharmaceutical companies in China. He worked as a junior consultant and was involved in the development of financial models for evaluating the listed pharmaceutical companies sector.

He has also gained experience in the commercial world with his family business, Mudanjiang Cigarette Materials Factory which is in the tobacco sector where he successfully helped negotiate a deal with Western raw material provider. He understands how Chinese business works and how to effectively collaborate with a Chinese company.

Shicai went to the University of Manchester where he studied Pharmacology (Hons).
He has a Masters degree in Biomedical Science from Royal Holloway, University of London. He will graduate in 2013 from University College London with a Ph.D. in oncology. During his Ph.D., he presented at several international cancer conferences and published five papers in well-recognized journals.
Back to top
© East West Capital Partners (EWCP). All Rights Reserved. Sitemap